AR065231A1 - Quinazolinas inhibidoras de pdk1, composiciones farmaceuticas que las contienen y usos para tratar enfermedades asociadas a proliferacion celular. - Google Patents
Quinazolinas inhibidoras de pdk1, composiciones farmaceuticas que las contienen y usos para tratar enfermedades asociadas a proliferacion celular.Info
- Publication number
- AR065231A1 AR065231A1 ARP070105879A ARP070105879A AR065231A1 AR 065231 A1 AR065231 A1 AR 065231A1 AR P070105879 A ARP070105879 A AR P070105879A AR P070105879 A ARP070105879 A AR P070105879A AR 065231 A1 AR065231 A1 AR 065231A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heteroaryloxy
- alkyl
- alkoxy
- heteroaryl
- Prior art date
Links
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 title 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 title 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- -1 carbonylamino, aminocarbonyl Chemical group 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004076 pyridyl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001733 carboxylic acid esters Chemical class 0.000 abstract 3
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 150000001356 alkyl thiols Chemical class 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 abstract 1
- 241000233001 Carios Species 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000003441 thioacyl group Chemical group 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Reivindicacion 1: Un compuesto de formula (1), o una sal aceptable para el uso farmacéutico, un éster, o un tautomero de éste, caracterizado porque: Ar es arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido; R1 es H, alquilo C1-3, halo, ciano, nitro, CF3, imidazolilo, tiazolilo, oxazolilo, o amino; R2 se selecciona del grupo que consiste en H, alcoxilo, alcoxilo sustituido, alquilo. alquilo sustituido, CN, heteroariloxilo, heteroariloxilo sustituido, heterocicliloxilo, heterocicliloxilo sustituido, y halo; R3 se selecciona del grupo que consiste en H, halo, CN, carboxilo, alquilo, alquilo sustituido, alcoxilo, alcoxilo sustituido, ariloxilo, ariloxilo sustituido, cicloalquiloxilo, cicloalquiloxilo sustituido, heterociclilalquiloxilo, heterociclilalquiloxilo sustituido, heteroariloxilo, heteroariloxilo sustituido, heteroarilalquiloxilo, heteroarilalquiloxilo sustituido, arilalquiloxilo, arilalquiloxilo sustituido, heteroarilo, heteroarilo sustituido, heterociclilo, heterociclilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, heterociclilalquilo, y heterociclilalquilo sustituido; L es un enlace covalente, carbonilo, carbonilamino, aminocarbonilo, -O-, -S- SO-, -SO2-, -NH-, alquilo C1-3, alquilo C1-3 sustituido, alquenilo C2-3, alquinilo C2-3 o un alquilo interrumpido con -O-, -S-, -SO-, o -SO2-; A1 es alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxilo, alcoxilo sustituido, acilo, acilamino, aciloxilo, amino, amino sustituido, aminocarbonilo, aminotiocarbonilo, aminocarbonilamino, aminotiocarbonilamino, aminocarboniloxilo, aminosulfonilo, aminosulfoniloxilo, arninosulfonilamino, amidino, carboxilo, éster carboxílico, (éster carboxílico)amino, (éster carboxílico)oxilo, cario, halo, hidroxilo, nitro, SO3H, sulfonilo, sulfonilo sustituido, sulfoniloxilo, sulfonilamino, tioacilo, tiol, alquiltiol, alquiltiol sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, cicloalquilo, cicloalquilo sustituido, heterociclilo, o heterociclilo sustituido, con las siguientes condiciones: a) cuando R1, R2, y R3 son cada uno H, y L es un enlace covalente, entonces A1 es distinto de arilo o arilo sustituido; b) cuando R1, R2, y R5 son cada uno H, L es un enlace covalente, y A1 es Br, fenilo sustituido, o piridinilo sustituido, entonces Ar es distinto de fenilo, fenilo sustituido con piperazinilo o heterociclilalquiloxilo, o piridinilo; c) cuando R1, R2, y R3 son cada uno H, L es un enlace covalente, y A1 es hidroxilo o alcoxilo, entonces Ar es distinto de fenilo sustituido con uno o más alquilo o halo: y d) cuando R1, R2, y R3 son cada uno H, y L es O entonces A1 es distinto de piridinilo o piridinilo sustituido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87697206P | 2006-12-22 | 2006-12-22 | |
| US99917007P | 2007-10-15 | 2007-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065231A1 true AR065231A1 (es) | 2009-05-27 |
Family
ID=39563215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105879A AR065231A1 (es) | 2006-12-22 | 2007-12-21 | Quinazolinas inhibidoras de pdk1, composiciones farmaceuticas que las contienen y usos para tratar enfermedades asociadas a proliferacion celular. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20100216767A1 (es) |
| EP (1) | EP2125755A2 (es) |
| JP (1) | JP2010514693A (es) |
| KR (1) | KR20090092287A (es) |
| CN (1) | CN101652352A (es) |
| AR (1) | AR065231A1 (es) |
| AU (1) | AU2007336893A1 (es) |
| BR (1) | BRPI0720563A2 (es) |
| CA (1) | CA2673003A1 (es) |
| CL (1) | CL2007003774A1 (es) |
| CO (1) | CO6361927A2 (es) |
| CR (1) | CR10833A (es) |
| EA (1) | EA200900819A1 (es) |
| EC (1) | ECSP099445A (es) |
| IL (1) | IL198774A0 (es) |
| MA (1) | MA31001B1 (es) |
| MX (1) | MX2009006627A (es) |
| NO (1) | NO20092725L (es) |
| PE (1) | PE20081630A1 (es) |
| SM (1) | SMP200900055B (es) |
| SV (1) | SV2009003307A (es) |
| TN (1) | TN2009000255A1 (es) |
| TW (1) | TW200829558A (es) |
| WO (1) | WO2008079988A2 (es) |
| ZA (1) | ZA200903233B (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| US20100311965A1 (en) * | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
| WO2009131173A1 (ja) * | 2008-04-23 | 2009-10-29 | 協和発酵キリン株式会社 | 2-アミノキナゾリン誘導体 |
| US20100121052A1 (en) * | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| WO2010011871A2 (en) * | 2008-07-23 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for providing salicylic acid-independent pathogen resistance in plants |
| ES2432414T3 (es) * | 2008-08-12 | 2013-12-03 | Glaxosmithkline Llc | Compuestos químicos |
| JP2012514020A (ja) * | 2008-12-29 | 2012-06-21 | フォーヴィア・ファーマシューティカルズ | 置換キナゾリン化合物 |
| CN102317288A (zh) | 2009-02-13 | 2012-01-11 | 佛维雅制药公司 | 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| AR081960A1 (es) | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| CN101921238B (zh) * | 2010-08-04 | 2012-04-04 | 苏州大学附属第一医院 | 取代苯并氮杂环类衍生物的制备及其药理用途 |
| JP5916730B2 (ja) * | 2010-09-06 | 2016-05-11 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ | アミド化合物 |
| EP2632263A1 (en) * | 2010-10-29 | 2013-09-04 | Merck Sharp & Dohme Corp. | Novel thiazole-carboxamide derivatives as pdk1 inhibitors |
| DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
| EP2642856B1 (en) | 2010-11-24 | 2017-07-19 | The Ohio State University Research Foundation | Integrin-linked kinase inhibitors |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| DE102011008352A1 (de) | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| AU2012317457B2 (en) * | 2011-09-29 | 2016-09-29 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| DK2872491T3 (da) * | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| GB201216018D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| TR201808812T4 (tr) | 2013-03-26 | 2018-07-23 | Ono Pharmaceutical Co | Fenil derivesi. |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| PT3027600T (pt) | 2013-07-31 | 2022-06-23 | Novartis Ag | Derivados de piridazina 1,4-dissubstituídos e a sua utilização para tratamento de condições relacionadas com deficiência em smn |
| EP3670496A3 (en) * | 2013-10-17 | 2020-09-30 | Shionogi&Co., Ltd. | Acc2 inhibitors |
| RS60136B1 (sr) | 2013-10-18 | 2020-05-29 | Celgene Quanticel Research Inc | Inhibitori bromodomena |
| EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| LT3122358T (lt) | 2014-03-26 | 2021-04-12 | Astex Therapeutics Ltd. | Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui |
| HUE053653T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR inhibitor és IGF1R inhibitor kombinációi |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| CA2979792C (en) * | 2015-02-24 | 2023-04-04 | Gene Techno Science Co., Ltd. | Method for diagnosing, preventing and treating cancer brain metastasis, and drug delivery system for enabling passage through blood-brain barrier |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CA2992945A1 (en) | 2015-07-17 | 2017-01-26 | Memorial Sloan-Kettering Cancer Center | Combination therapy using pdk1 and pi3k inhibitors |
| HRP20220012T1 (hr) | 2015-09-23 | 2022-04-01 | Janssen Pharmaceutica Nv | Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka |
| CN108026095B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 新化合物 |
| EP3868751B1 (en) | 2015-10-02 | 2023-10-25 | Sentinel Oncology Limited | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| HUE061607T2 (hu) | 2017-10-18 | 2023-07-28 | Jubilant Epipad LLC | Imidazopiridin vegyületek mint PAD inhibitorok |
| CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
| AU2019234185A1 (en) | 2018-03-13 | 2020-10-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
| US20230399327A1 (en) * | 2020-10-28 | 2023-12-14 | Adlai Nortye Biopharma Co., Ltd. | High activity hpk1 kinase inhibitor |
| CN113999206B (zh) * | 2021-12-31 | 2022-04-12 | 北京鑫开元医药科技有限公司 | 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用 |
| CN114533733A (zh) * | 2021-12-31 | 2022-05-27 | 北京鑫开元医药科技有限公司 | 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法 |
| WO2023138412A1 (en) * | 2022-01-20 | 2023-07-27 | Insilico Medicine Ip Limited | Fused pyrimidin-2-amine compounds as cdk20 inhibitors |
| WO2023218241A1 (en) * | 2022-05-13 | 2023-11-16 | Voronoi Inc. | Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006118256A1 (ja) * | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | 2-アミノキナゾリン誘導体 |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| WO2008020203A1 (en) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
| TW200829566A (en) * | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
-
2007
- 2007-12-20 EA EA200900819A patent/EA200900819A1/ru unknown
- 2007-12-20 US US12/448,390 patent/US20100216767A1/en not_active Abandoned
- 2007-12-20 CN CN200780047581A patent/CN101652352A/zh active Pending
- 2007-12-20 KR KR1020097012780A patent/KR20090092287A/ko not_active Application Discontinuation
- 2007-12-20 WO PCT/US2007/088392 patent/WO2008079988A2/en active Application Filing
- 2007-12-20 JP JP2009543225A patent/JP2010514693A/ja not_active Withdrawn
- 2007-12-20 MX MX2009006627A patent/MX2009006627A/es not_active Application Discontinuation
- 2007-12-20 EP EP07869660A patent/EP2125755A2/en not_active Withdrawn
- 2007-12-20 CA CA002673003A patent/CA2673003A1/en not_active Abandoned
- 2007-12-20 BR BRPI0720563-5A patent/BRPI0720563A2/pt not_active IP Right Cessation
- 2007-12-20 AU AU2007336893A patent/AU2007336893A1/en not_active Abandoned
- 2007-12-21 AR ARP070105879A patent/AR065231A1/es unknown
- 2007-12-21 CL CL200703774A patent/CL2007003774A1/es unknown
- 2007-12-21 TW TW096149570A patent/TW200829558A/zh unknown
-
2008
- 2008-01-02 PE PE2008000067A patent/PE20081630A1/es not_active Application Discontinuation
-
2009
- 2009-05-11 ZA ZA200903233A patent/ZA200903233B/xx unknown
- 2009-05-14 IL IL198774A patent/IL198774A0/en unknown
- 2009-05-28 CR CR10833A patent/CR10833A/es not_active Application Discontinuation
- 2009-06-17 MA MA32005A patent/MA31001B1/fr unknown
- 2009-06-17 CO CO09062868A patent/CO6361927A2/es not_active Application Discontinuation
- 2009-06-19 TN TNP2009000255A patent/TN2009000255A1/fr unknown
- 2009-06-19 EC EC2009009445A patent/ECSP099445A/es unknown
- 2009-06-19 SV SV2009003307A patent/SV2009003307A/es not_active Application Discontinuation
- 2009-06-30 SM SM200900055T patent/SMP200900055B/it unknown
- 2009-07-17 NO NO20092725A patent/NO20092725L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008079988A2 (en) | 2008-07-03 |
| CR10833A (es) | 2009-07-03 |
| EA200900819A1 (ru) | 2010-02-26 |
| TN2009000255A1 (en) | 2010-10-18 |
| JP2010514693A (ja) | 2010-05-06 |
| SMAP200900055A (it) | 2009-09-07 |
| MX2009006627A (es) | 2009-08-12 |
| US20100216767A1 (en) | 2010-08-26 |
| SV2009003307A (es) | 2010-05-21 |
| CL2007003774A1 (es) | 2008-04-18 |
| TW200829558A (en) | 2008-07-16 |
| PE20081630A1 (es) | 2008-12-14 |
| BRPI0720563A2 (pt) | 2014-02-04 |
| KR20090092287A (ko) | 2009-08-31 |
| AU2007336893A1 (en) | 2008-07-03 |
| WO2008079988A9 (en) | 2011-05-12 |
| WO2008079988A3 (en) | 2008-10-16 |
| CA2673003A1 (en) | 2008-07-03 |
| EP2125755A2 (en) | 2009-12-02 |
| MA31001B1 (fr) | 2009-12-01 |
| NO20092725L (no) | 2009-09-22 |
| SMP200900055B (it) | 2010-05-07 |
| CN101652352A (zh) | 2010-02-17 |
| ZA200903233B (en) | 2010-04-28 |
| IL198774A0 (en) | 2010-02-17 |
| CO6361927A2 (es) | 2012-01-20 |
| ECSP099445A (es) | 2009-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065231A1 (es) | Quinazolinas inhibidoras de pdk1, composiciones farmaceuticas que las contienen y usos para tratar enfermedades asociadas a proliferacion celular. | |
| AR060358A1 (es) | Quinazolinas para la inhibicion de pdk 1 | |
| ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
| AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
| ES2594556T3 (es) | Derivado de naftaleno | |
| ES2572155T3 (es) | Compuestos insecticidas | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
| RS51451B (en) | PIRIDINE CARBOXAMIDES AS INHIBITORS OF 11-BETA-HSD1 | |
| RU2015116670A (ru) | Гетероциклические соединения в качестве пестицидов | |
| RS52679B (en) | RENIN INHIBITORS | |
| AR015765A1 (es) | Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento. | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| RS51995B (en) | NEW UNITS AS OPIOID RECEPTOR MODULATORS | |
| PE20091974A1 (es) | Derivados de indazoles sustituidos con fenil o piridinilo | |
| PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
| AR064130A1 (es) | Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas. | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR074238A1 (es) | Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende | |
| AR069764A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| CO6361934A2 (es) | Composicion farmaceutica solida | |
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| TW200510353A (en) | Alpha substituted carboxylic acids as PPAR modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |